
Neuro biotech Rapport builds investor confidence with $150M Series B, giving it optionality for IPO
Just five months after emerging with $100 million to test former Janssen neuroscience programs, Rapport Therapeutics is back with another nine-figure raise to take its lead small molecule through mid-stage trials. The California and Massachusetts […]